| Nov 15 |
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
| Nov 13 |
Erasca reports Q3 results
|
| Nov 12 |
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
|
| Nov 5 |
Erasca to Present at Upcoming Investor Conferences
|
| Oct 30 |
Erasca Insiders Added US$1.95m Of Stock To Their Holdings
|
| Oct 24 |
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
|
| Sep 30 |
Erasca: New Focus After Restructuring, But Need More Differentiation
|
| Sep 25 |
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
|
| Sep 23 |
Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company
|
| Aug 29 |
Erasca to Present at Upcoming Investor Conferences in September
|
